# A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

> **NCT01323270** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 753 (actual)

## Conditions studied

- Meningococcal Vaccine
- rLP2086
- Repevax
- N Meningitidis Serogroup B
- Meningitis

## Interventions

- **BIOLOGICAL:** rLP2086
- **BIOLOGICAL:** Repevax
- **BIOLOGICAL:** Saline
- **BIOLOGICAL:** Repevax

## Key facts

- **NCT ID:** NCT01323270
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-18
- **Primary completion:** 2012-10-08
- **Final completion:** 2013-02-19
- **Target enrollment:** 753 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323270, "A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01323270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*